Objective: To assess the effectivenessof apheresis therapy (AT) in treating the clinical manifestations of patients with complicated cryoglobulinemic vasculitis (CV). Methods: A retrospective cohort study of 159 CV patients attending 22 Italian Centers who underwent at least one AT session between 2005 and 2015. The response to AT was evaluated on the basis of a defined grading system. Results: Peripheral neuropathy was the most frequent clinical condition leading to AT. Therapeutic plasma exchange was used in 70.4% of cases. The outcome of AT was rated very good in 19 cases, good in 64, partial/transient in 40, and absent/not assessable in 36. Life-threatening CV-related emergencies and renal impairment independently correlated with failure to respond to AT. The independent variables associated with an increased risk of death were age at the time of the first AT session, multi-organ life-threatening CV, the presence of renal impairment and failure to respond to AT. The time-dependent probability of surviving until CV-related death in the second year was 84%, with an AHR in patients with absent/not assessable response to AT of 11.25. Conclusion: In this study AT is confirmed to be a safe procedure in patients with CV. Early AT should be considered in patients with severe CV, especially in cases with impending renal involvement, in order to prevent irreversible kidney damage. Although its efficacy in patients with multi-organ failure is limited, AT is the only treatment that can rapidly remove circulating cryoglobulins, and should be considered an emergency treatment.

Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients / Marson, P.; Monti, G.; Montani, F.; Riva, A.; Mascia, M. T.; Castelnovo, L.; Filippini, D.; Capuzzo, E.; Moretto, M.; D'Alessandri, G.; Marenchino, D.; Zani, R.; Fraticelli, P.; Ferri, C.; Quartuccio, L.; De Silvestro, G.; Oreni, L.; Accorsi, P.; Galli, M.. - In: TRANSFUSION AND APHERESIS SCIENCE. - ISSN 1473-0502. - 57:5(2018), pp. 639-645. [10.1016/j.transci.2018.06.005]

Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients

Mascia, M. T.;Ferri, C.;
2018

Abstract

Objective: To assess the effectivenessof apheresis therapy (AT) in treating the clinical manifestations of patients with complicated cryoglobulinemic vasculitis (CV). Methods: A retrospective cohort study of 159 CV patients attending 22 Italian Centers who underwent at least one AT session between 2005 and 2015. The response to AT was evaluated on the basis of a defined grading system. Results: Peripheral neuropathy was the most frequent clinical condition leading to AT. Therapeutic plasma exchange was used in 70.4% of cases. The outcome of AT was rated very good in 19 cases, good in 64, partial/transient in 40, and absent/not assessable in 36. Life-threatening CV-related emergencies and renal impairment independently correlated with failure to respond to AT. The independent variables associated with an increased risk of death were age at the time of the first AT session, multi-organ life-threatening CV, the presence of renal impairment and failure to respond to AT. The time-dependent probability of surviving until CV-related death in the second year was 84%, with an AHR in patients with absent/not assessable response to AT of 11.25. Conclusion: In this study AT is confirmed to be a safe procedure in patients with CV. Early AT should be considered in patients with severe CV, especially in cases with impending renal involvement, in order to prevent irreversible kidney damage. Although its efficacy in patients with multi-organ failure is limited, AT is the only treatment that can rapidly remove circulating cryoglobulins, and should be considered an emergency treatment.
2018
26-giu-2018
57
5
639
645
Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients / Marson, P.; Monti, G.; Montani, F.; Riva, A.; Mascia, M. T.; Castelnovo, L.; Filippini, D.; Capuzzo, E.; Moretto, M.; D'Alessandri, G.; Marenchino, D.; Zani, R.; Fraticelli, P.; Ferri, C.; Quartuccio, L.; De Silvestro, G.; Oreni, L.; Accorsi, P.; Galli, M.. - In: TRANSFUSION AND APHERESIS SCIENCE. - ISSN 1473-0502. - 57:5(2018), pp. 639-645. [10.1016/j.transci.2018.06.005]
Marson, P.; Monti, G.; Montani, F.; Riva, A.; Mascia, M. T.; Castelnovo, L.; Filippini, D.; Capuzzo, E.; Moretto, M.; D'Alessandri, G.; Marenchino, D.; Zani, R.; Fraticelli, P.; Ferri, C.; Quartuccio, L.; De Silvestro, G.; Oreni, L.; Accorsi, P.; Galli, M.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1473050218301423-main.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 424.29 kB
Formato Adobe PDF
424.29 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1182420
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 25
social impact